IMDX vs SYF · rev $271.0K vs rev $11.19B
Insight Molecular Diagnostics Inc. (IMDX) versus SYF (SYF) — a side-by-side from cached financials, not a winner call.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
SYF (SYF) common stock.
Latest reported IMDX revenue for 2026-06-30 was $271.0K. Net income was -$15.6M. IMDX currently screens at market cap $0.
Latest reported SYF revenue for 2026-06-30 was $11.19B. Net income was $1.69B. Revenue was up 99.6% from 2026-03-31 to 2026-06-30. SYF currently screens at market cap $0.
IMDX currently screens at market cap $0. SYF currently screens at market cap $0.
Not investment advice. Open the IMDX and SYF stock pages for the full models.
Not investment advice.